Publications by authors named "Cal Cohen"

Claim this Profile
A
Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravir.
Michelle L D'Antoni, Brie Falkard, Kristen Andreatta, Stephanie Cox, Cal Cohen

J Antimicrob Chemother· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.
Eric S Daar, Chloe Orkin, Paul E Sax, Debbie Hagins, Anton Pozniak, Cal Cohen

AIDS Res Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrase Strand Transfer Inhibitor-Related Changes in Body Mass Index and Risk of Diabetes: A Prospective Study From the RESPOND Cohort Consortium.
Dhanushi Rupasinghe, Loveleen Bansi-Matharu, Matthew Law, Robert Zangerle, Andri Rauch, Cal Cohen

Clin Infect Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Dathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, Andri Rauch, Katharina Grabmeier-Pfistershammer, Cal Cohen

Lancet HIV· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes.
Amanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, Josep M Llibre, Bastian Neesgaard, Cal Cohen

AIDS· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression.
Jose R Castillo-Mancilla, Mary Morrow, Peter W Hunt, Samuel R Schnittman, Andrew N Phillips, Cal Cohen

Open Forum Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
Joy Y Feng, Venice Du Pont, Darius Babusis, Calvin J Gordon, Egor P Tchesnokov, Cal Cohen

Molecules· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.
Kristine M Erlandson, Christoph C Carter, Kathleen Melbourne, Todd T Brown, Cal Cohen

Clin Infect Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
Danielle P Porter, Martin Daeumer, Alexander Thielen, Silvia Chang, Ross Martin, Cal Cohen

Viruses· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stalemate--but not checkmate. An expert takes on the challenges. Interview by Jeff Berry.
Cal Cohen

Posit Aware· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.
Zoe Fox, Andrew Phillips, Cal Cohen, Jacquie Neuhaus, John Baxter

AIDS· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiretroviral treatment update from the 17th International AIDS Conference.
Brian Boyle, Cal Cohen, Edwin DeJesus, Richard Elion, Ian Frank

AIDS Read· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable suppression possible with FOTO treatment schedule in subjects on nevirapine-based regimens.
Cal Cohen, Amy Colson

HIV Clin Trials· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.
Andrew Hill, Howard Grossman, Cal Cohen, Jeff Nadler, Monika Peeters

HIV Clin Trials· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Issues in the design of trials comparing management strategies for heavily pretreated patients.
Andrew N Phillips, Cal Cohen, Jens D Lundgren

Curr Opin HIV AIDS· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HAART at 10: an interview with Cal Cohen.
Cal Cohen

Res Initiat Treat Action· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekend treatment interruptions for certain well-controlled patients: interview with Cal Cohen, M.D. Interview by John S. James.
Cal Cohen

AIDS Treat News· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New fixed dose once-a-day combinations. Interview by John S. James.
Cal Cohen

IAPAC Mon· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals.
Mike Youle, Cal Cohen, Christine Katlama, Dan Kuritzkes, Sharon Walmsley

Lancet· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New fixed-dose once-a-day starting regimens: interview with Cal Cohen, M.D. Interview by John S. James.
Cal Cohen

AIDS Treat News· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment interruption; advanced HIV; new ideas: Dr. Cal Cohen interview on retrovirus conference (part 2 or 2). Interview by John S. James.
Cal Cohen

AIDS Treat News· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retroviruses Conference clinical news; interview with Cal Cohen, M.D. Interview by John S. James.
Cal Cohen

AIDS Treat News· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
Pablo Tebas, Keith Henry, Kristin Mondy, Steven Deeks, Herman Valdez, Cal Cohen

J Infect Dis· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis